Clinical-stage biotechnology companies are playing an increasingly important role in the development of new medicines. These companies typically have one or more drug candidates being evaluated in human clinical trials, placing them beyond the earliest laboratory research stage but still short of full commercial approval for those products. The clinical-stage segment includes companies working across oncology, immunology, rare diseases, neurological disorders, metabolic conditions, infectious diseases, gene therapy, cell therapy, RNA medicines, and other emerging areas.
A clinical-stage biotech company has progressed from laboratory and preclinical research into human testing.
Drug development generally follows several broad stages:
A company may have several candidates at different stages simultaneously.
Clinical-stage companies can therefore range from businesses conducting their first human trial to organizations preparing a late-stage drug candidate for regulatory submission.
Clinical development provides investors, pharmaceutical companies, and researchers with more information than laboratory research alone.
Human trials can generate evidence about:
However, reaching clinical development does not guarantee regulatory approval or commercial success.
A candidate can fail because of safety concerns, insufficient efficacy, manufacturing difficulties, trial design problems, competition, or commercial considerations.
Financing has become more selective.
S&P Global reported that U.S. biotech venture-backed funding rounds fell 25.2% year over year to 237 in 2025, while transaction value declined 8.19% to $13.3 billion. Investors increasingly favored companies with established clinical validation.
At the same time, the first half of 2026 showed stronger activity among companies already advancing clinical programs. BioPharma Dive reported that at least 68 biotech companies raised more than $9.1 billion in venture capital during the first six months of 2026, with most of the companies already having drugs in testing.
This creates an important distinction between overall biotech funding and funding for individual companies.
Capital may still be flowing into the sector, but investors are increasingly looking for evidence that a company's science can translate into clinical progress.
Clinical data have become particularly important in determining which biotech companies attract financing.
A company with:
may attract considerably more attention than a company whose primary asset remains in preclinical development.
This shift can influence financing structures, partnerships, acquisitions, and valuations.
Artificial intelligence remains one of the major technology trends affecting biotechnology in 2026.
AI is being used across areas such as:
EY reported that more than 88% of biobucks AI investment was concentrated in research and development, particularly target identification, drug design, and clinical-trial patient recruitment.
Investors continue to support AI-native biotech companies despite the fact that AI-generated drug discovery has not yet produced a U.S.-approved medicine. The Financial Times reported that investment in AI-driven drug discovery reached $2.2 billion in 2025, up from $599 million in 2023.
The implication is that investors are increasingly betting on the potential of AI to improve the drug-development process rather than relying solely on current approved products.
AI is also moving beyond drug discovery.
Recent research suggests that AI tools can improve clinical-trial operations by helping with:
A study from the Tufts Center for the Study of Drug Development reported that AI-assisted processes could reduce late-stage clinical-trial timelines by around 10 weeks in certain settings.
However, AI does not eliminate the fundamental challenges of clinical research.
Patient recruitment, informed consent, trial execution, regulatory requirements, and reliable clinical data remain essential.
Cancer remains one of the largest areas of biotech research and investment.
Clinical-stage companies are developing therapies involving:
The attractiveness of oncology reflects both the size of the patient population and the continuing need for treatments that improve survival and quality of life.
Competition is also intense, meaning clinical differentiation is increasingly important.
Immunology is another major area of biotech activity.
Companies are investigating treatments for diseases such as:
Recent clinical results demonstrate how established biotech platforms can expand into additional indications. For example, argenx reported positive Phase 3 results for Vyvgart in autoimmune myositis, potentially expanding an established therapy into another area of autoimmune medicine.
Metabolic disease has become one of the most commercially important areas of pharmaceutical research.
GLP-1 medicines have created a large market for obesity and diabetes treatment, while clinical-stage companies and major pharmaceutical manufacturers are developing next-generation approaches.
Research is expanding into:
Recent industry activity shows continued interest in therapies that can deliver substantial weight reduction while reducing gastrointestinal side effects.
Rare diseases remain a major area for clinical-stage biotechnology.
The sector is attractive because many rare diseases have limited treatment choices and well-defined patient populations.
Clinical-stage companies are developing:
Rare-disease development can also benefit from regulatory incentives designed to encourage treatments for conditions affecting relatively small patient populations.
Gene and cell therapies continue to represent important areas of innovation.
These approaches can involve:
Clinical development can be technically complex because manufacturing, delivery, durability, safety, and long-term monitoring all matter.
The field therefore creates opportunities for specialized clinical-stage companies with proprietary technologies and manufacturing capabilities.
RNA technologies remain another important area.
Biotech companies are developing therapies based on:
These technologies can potentially address diseases that have historically been difficult to treat with conventional small molecules.
However, delivery remains an important technical challenge for many RNA platforms.
The geographic center of biotech innovation is also becoming more international.
EY reported that 39% of U.S. biobucks flowed to China and highlighted expanding R&D investment in China as an important factor shaping innovation.
Industry leaders are increasingly paying attention to Chinese biotech companies as sources of clinical assets, licensing opportunities, and scientific innovation.
This has also created geopolitical considerations involving intellectual property, supply chains, investment restrictions, and pharmaceutical partnerships.
Large pharmaceutical companies increasingly rely on partnerships with biotechnology companies to replenish their pipelines.
Transactions can involve:
Clarivate reported that global biopharma dealmaking reached a record $292.6 billion in 2025, driven partly by fewer but larger transactions and increasing global sourcing of innovation.
For clinical-stage biotech companies, a partnership with a larger pharmaceutical company can provide funding, development expertise, manufacturing capabilities, and commercialization resources.
Another important area is the growth of biosimilars.
As exclusivity periods for major biologic medicines expire, companies are developing biosimilar versions that can potentially expand treatment access and create competition.
A recent Sandoz agreement with Shanghai Henlius illustrates the continued international interest in biosimilar development. The deal covers biosimilars of evolocumab, belimumab, and cetuximab, with potential deal value reaching hundreds of millions of dollars depending on milestones.